SCHEMBL2477396

SCHEMBL2477396

CC(C)(C)OC(=O)Nc1ccccc1NC(=O)c1ccc(CN(CCCN2CCOCC2)C(=O)Nc2nccs2)cc1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CASR P41180 1/20 0.49
OPRM1 P35372 1/20 0.46
OPRD1 P41143 1/20 0.46
TSHR P16473 2/20 0.45
CYP2D6 P10635 1/20 0.45
ADORA2A P29274 1/20 0.45
USP2 O75604 1/20 0.44
METAP1 P53582 1/20 0.44
TRPV4 Q9HBA0 1/20 0.43
ALDH1A1 P00352 3/20 0.42
CD274 Q9NZQ7 1/20 0.42
KDM1A O60341 1/20 0.41
LMNA P02545 1/20 0.40
NAMPT P43490 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
ROCK2 O75116 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4224152 0.92 CASR (0.48) CASROPRM1OPRD1TSHRUSP2
SCHEMBL4234580 0.90 CASR (0.48) CASROPRM1OPRD1TSHRUSP2
SCHEMBL2502499 0.87 CASR (0.53) CASROPRM1OPRD1TSHRCYP2D6
SCHEMBL3835326 0.86 OPRM1 (0.49) CASROPRM1OPRD1TSHRUSP2
SCHEMBL2499135 0.85 USP2 (0.42) OPRM1OPRD1TSHRCYP2D6USP2
SCHEMBL4233290 0.85 METAP1 (0.45) CASROPRM1OPRD1TSHRADORA2A
SCHEMBL3832709 0.85 USP2 (0.55) CASROPRM1OPRD1TSHRUSP2
SCHEMBL4399525 0.85 OPRM1 (0.41) CASROPRM1OPRD1TSHRUSP2
SCHEMBL2475683 0.85 HDAC1 (0.54) TSHRALDH1A1CD274KDM1ALMNA
SCHEMBL2479082 0.85 OPRM1 (0.51) OPRM1OPRD1TSHRUSP2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8076332-B2 N- (2-aminophenyl) benzamide derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-12-13 US disclosed
US-8076332-B2 N- (2-aminophenyl) benzamide derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-12-13 US disclosed
US-8076332-B2 N- (2-aminophenyl) benzamide derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-12-13 US disclosed
EP-2107052-B1 NOVEL N-(2-AMINOPHENYL)BENZAMIDE DERIVATIVE HAVING AN UREA STRUCTURE SANTEN PHARMACEUTICAL CO LTD (JP) 2011-10-12 EP disclosed
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed
EP-2107052-A1 NOVEL N-(2-AMINOPHENYL)BENZAMIDE DERIVATIVE HAVING AN UREA STRUCTURE Santen Pharmaceutical Co., Ltd (JP) 2009-10-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE UACA, SLC14A1, ARG2 CASR 3264/4885OPRM1 1105/4885OPRD1 1211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.